Background: Vitamin D has been proposed as a promoter of immune homeostasis in multiple sclerosis (MS). During the past decade, the focus of the effects of vitamin D has been on dendritic cells and on T cells. Since there is an increasing interest in the role of B cells in the pathophysiology of MS, we studied the role of vitamin D on B cells in vivo in patients with MS.
Objective: We explored the effects of 12 weeks high-dose vitamin D3 supplementation on peripheral B cell differentiation, immunoglobulin production and levels of B cell activating factor (BAFF) in 15 patients with MS.
Methods: Circulating B cell subsets were characterized by flow cytometry. Plasma immunoglobulin levels were assessed by nephelometry. Plasma BAFF levels were assessed by enzyme-linked immunosorbent assay (ELISA).
Results: Although a significant increase serum 25-hydroxyvitamin D was induced, we found no significant shift in B cell differentiation, isotype switching, or plasma BAFF levels.
Conclusion: In patients with MS, supplementation of high doses vitamin D3 does not have substantial effects on phenotypic markers of B cell differentiation in circulating B cells. Future studies may unravel more subtle changes in the B cell compartment, either in the circulation or in the central nervous system.
AscherioAMungerKLSimonKC. Vitamin D and multiple sclerosis. Lancet Neurol2010; 9: 599–612.
2.
SmoldersJDamoiseauxJMenheerePHuppertsR. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol2008; 194: 7–17.
3.
SimpsonSJr.TaylorBBlizzardL. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol2010; 68: 193–203.
4.
SmoldersJMenheerePKesselsADamoiseauxJHuppertsR. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler2008; 14: 1220–1224.
5.
van der MeiIAPonsonbyALDwyerT. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol2007; 254: 581–590.
6.
CorrealeJYsrraelitMCGaitanMI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain2009; 132: 1146–1160.
7.
SmoldersJThewissenMPeelenE. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One2009; 4: e6635.
8.
BurtonJMKimballSViethR. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010; 74: 1852–1859.
9.
SmoldersJPeelenEThewissenM. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One2010; 5: e15235.
10.
DalakasMC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol2008; 4: 557–567.
11.
FranciottaDSalvettiMLolliFSerafiniBAloisiF. B cells and multiple sclerosis. Lancet Neurol2008; 7: 852–858.
12.
HauserSLWaubantEArnoldDL. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med2008; 358: 676–688.
13.
HedegaardCJSellebjergFKrakauerMHesseDBendtzenKNielsenCH. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult Scler2010; Published as doi: 10.1177/135245851039377110.1177/1352458510393771.
14.
ChenSSimsGPChenXXGuYYLipskyPE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol2007; 179: 1634–1647.
15.
ChenWCVayuvegulaBGuptaS. 1,25-Dihydroxyvitamin D3-mediated inhibition of human B cell differentiation. Clin Exp Immunol1987; 69: 639–646.
16.
IhoSTakahashiTKuraFSugiyamaHHoshinoT. The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells. J Immunol1986; 136: 4427–4431.
17.
LemireJMAdamsJSSakaiRJordanSC. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest1984; 74: 657–661.
18.
AgematsuKHokibaraSNagumoHKomiyamaA. CD27: a memory B-cell marker. Immunol Today2000; 21: 204–206.
19.
PascualVLiuYJMagalskiAde BouteillerOBanchereauJCapraJD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med1994; 180: 329–339.
20.
KabatEAGlusmanMKnaubV. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med1948; 4: 653–662.
21.
SerafiniBRosicarelliBMagliozziRStiglianoEAloisiF. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol2004; 14: 164–174.
22.
Bar-OrAFawazLFanB. Abnormal B-cell cytokine responses: a trigger of T-cell-mediated disease in MS?. Ann Neurol2010; 67: 452–461.
23.
DuddyMNiinoMAdatiaF. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol2007; 178: 6092–6099.
24.
BinardALe PottierLDevauchelle-PensecVSarauxAYouinouPPersJO. Is the blood B-cell subset profile diagnostic for Sjögren syndrome?. Ann Rheum Dis2009; 68: 1447–1452.
25.
SanzIWeiCLeeFEAnolikJ. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol2008; 20: 67–82.
26.
YouinouPRenaudineauY. The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev2007; 7: 149–154.
27.
GriffinDOHolodickNERothsteinTL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med2011; 208: 67–80.
28.
HirotaniMNiinoMFukazawaT. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol2010; 221: 95–100.
29.
HeineGNiesnerUChangHD. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur J Immunol2008; 38: 2210–2218.
30.
ProvvediniDMTsoukasCDDeftosLJManolagasSC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science1983; 221: 1181–1183.
31.
HoWYCookeMPGoodnowCCDavisMM. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J Exp Med1994; 179: 1539–1549.
32.
MetlayJPPureESteinmanRM. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immunol1989; 47: 45–116.
33.
SchneiderP. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol2005; 17: 282–289.
34.
KrumbholzMTheilDDerfussT. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med2005; 201: 195–200.
35.
HuntingtonNDTomiokaRClavarinoC. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol2006; 18: 1473–1485.
36.
KrumbholzMFaberHSteinmeyerF. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain2008; 131: 1455–1463.
37.
NiinoMHirotaniMMiyazakiYSasakiH. Memory and naive B-cell subsets in patients with multiple sclerosis. Neurosci Lett2009; 464: 74–78.
38.
RamgolamVSShaYMarcusKL. B Cells as a Therapeutic Target for IFN-{beta} in Relapsing-Remitting Multiple Sclerosis. J Immunol2011; 186: 4518–4526.
39.
SmoldersJHuppertsRBarkhofFGrimaldiLHolmoyTKillesteinJ. Efficacy of vitamin D3 as add-on therapy in patients with relapsing -remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase 2, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci2011, published as doi:10.1016/j.jns.2011.04.01310.1016/j.jns.2011.04.013.
40.
VogtMHten KateJDrentRJPolmanCHHuppertsR. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler2010; 16: 443–449.
